Biotechnology
13 August 2025 Plaintiff accuses defendant of “locking” employees out of office to steal secrets | Ruling rejects California’s stricter “reasonable particularity” rule for federal DTSA cases | Decision may shape plaintiffs’ choice of legal claims in future disputes in the state.
Latest Features
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Africa
Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
Key similarities and differences between the patent systems, particularly in biotech, offer lessons and opportunities for rightsholders, say Daniela Fasoli of Simões Propriedade Intelectual and Jeffrey Morton of Haynes and Boone.
Asia
Free trade zones in Beijing, Shanghai, Guangdong, and Hainan are designed to attract capital into China’s fast-growing healthcare sectors, says Li Mi of Lusheng.
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips.
More News
16 July 2025 LSPN experts from Goodwin Law, Invivyd, and New England Biolabs discuss the challenges of patent eligibility under 35 U.S.C. § 101 in life sciences innovation. The session explores strategies to address obstacles arising from recent court decisions and USPTO guidelines.
15 July 2025 After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.
8 July 2025 LSPN brings together experts from Venable, Ipsen, Stoke Therapeutics, and Biogen to analyse best practices for IP transactions, from due diligence and valuation to structuring deals.
3 July 2025 Board of Appeal upholds opposition challenge over added subject-matter claims | Dispute concerned patent relating to T cell therapeutic manufacturing methods.
2 July 2025 Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.
1 July 2025 Judge says sale of genetic data is ‘scary proposition’ but that blanket ban could result in missed opportunities | Former CEO Anne Wojcicki will repurchase business that she co-founded and ran for years.
26 June 2025 Biotech institute successfully challenges EPO decision revoking key CRISPR patent over priority rights | Appeal follows major changes to European law | Case returns to lower court for novelty and inventive step evaluation.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox